
Toxicity study considerations for HIV prevention and MPT R&D
This third webinar in the IMPT’s “Let’s Talk MPTs” series provides MPT and HIV prevention product developers and other stakeholders with an overview of strategies to assess the toxicity of MPT drug candidates and describe the potential toxicity risks of pharmaceutical substances to the female reproductive tract. Featured discussants were clinical infectious disease specialist Thomas Moench, MD, of Mapp Biopharmaceutical and Mucommune LLC, and Miles Brennan, PhD, a genetic engineering specialist currently focusing on monoclonal antibodies for infectious diseases at ZabBio, Inc.
View Webinar Recording
Download Presentation
Download Suggested Readings
May 2021
Click for full info +Full Info:
Resource Type:
Citation:
This third webinar in the IMPT’s “Let’s Talk MPTs” series provides MPT and HIV prevention product developers and other stakeholders with an overview of strategies to assess the toxicity of MPT drug candidates and describe the potential toxicity risks of pharmaceutical substances to the female reproductive tract. Featured discussants were clinical infectious disease specialist Thomas Moench, MD, of Mapp Biopharmaceutical and Mucommune LLC, and Miles Brennan, PhD, a genetic engineering specialist currently focusing on monoclonal antibodies for infectious diseases at ZabBio, Inc.
Authors: The IMPT, Thomas Moench, Miles Brennan
Health Risks(s):
- HIV
- STI / STD
- Unintended Pregnancy
Product type(s):
- Antibodies
- MPTs
Topic(s):
- MPTs
- Development
- Trials
- Regulatory
- Reproductive Health
- Risk
Region(s)
- Global